X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding aims to support the company's ongoing development of GM-3009 (ibogaine), a Kappa opioid receptor agonist. It is evaluated in the Preclinical trials for the treatment of Opioid-Related Disorders.
Lead Product(s): Ibogaine
Therapeutic Area: Psychiatry/Psychology Product Name: GM-3009
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 14, 2024
Details:
GM-1020 is a novel, oral NMDA receptor antagonist with the potential of advancing a new treatment option for patients with major depressive disorders and other neuropsychiatric conditions.
Lead Product(s): GM-1020
Therapeutic Area: Psychiatry/Psychology Product Name: GM-1020
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
GM-1020 is a novel, patented (composition of matter), orally active small molecule antagonist of the N-methyl-D-aspartate (NMDA) receptor with the potential to have rapid-acting antidepressant (RAAD) activity without adverse behavioral effects at therapeutic doses.
Lead Product(s): GM-1020
Therapeutic Area: Psychiatry/Psychology Product Name: GM-1020
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Prime Movers Lab
Deal Size: $39.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
